Journey West: How One Small Chinese Firm Is Taking On The World
Global Place For Affordable AMD Option?
Executive Summary
When it kicked off a pivotal study in 32 countries, a small Chengdu-based company stepped into unknown waters littered with challenges, ranging from lack of expertise to limited enthusiasm for a made in China new drug, from controls over foreign currency outflows to vetting investigators in foreign lands. But a strong early performance at home has given Kanghong confidence to take on big pharma and the world.
You may also be interested in...
China Rings In New Year With Major Deals, Record IPOs And Trends To Watch
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.